MALVERN, PA–Apr 28, 2009 — Auxilium Pharmaceuticals, Inc. (NasdaqGS:AUXL ), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status to its Biologic…
Biopharmaceuticals, FDA
Auxilium Pharmaceuticals, XIAFLEX, collagenase, Dupuytren’s contracture

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “XIAFLEX(TM) for the Treatment of Dupuytren’s Contracture Receives Priority Review From the U.S. Food and Drug Administration”
Leave a Comment